Restricted accessResearch articleFirst published online 2013-3
Reversal of Parenteral Nutrition–Associated Liver Disease With a Fish Oil–Based Lipid Emulsion (Omegaven) in an Adult Dependent on Home Parenteral Nutrition
Patients with intestinal failure and short bowel syndrome usually require chronic parenteral nutrition (PN). PN is associated with risks, including infections, vascular thrombosis, and liver disease. PN-associated liver disease (PNALD) can progress from steatosis to chronic hepatitis and ultimately to cirrhosis. The etiology of PNALD is not completely understood. Therapies for PNALD include carbohydrate or lipid calorie reduction, antibiotics, or the use of ursodeoxycholic acid. When these efforts fail, therapeutic options are limited and liver transplantation may be required. The transition from a soybean- to a fish oil–based lipid formulation, such as the ω-3 parenteral lipid formulation (Omegaven), has shown a dramatic reversal of PNALD within the pediatric population. This is the first report of a PN-dependent adult in the United States complicated by PNALD and hepatic failure who had improvement of liver disease with an ω-3 fish oil–based parenteral formulation.
HowardLAmentMFlemingCRShikeMSteigerE. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology. 1995;109(2):355-365.
2.
BuchmanAL. Complications of long-term home total parenteral nutrition: their identification, prevention and treatment. Dig Dis Sci. 2001;46(1): 1-18.
3.
FreundHR. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. Nutrition. 1991;7(1):1-5; discussion 5-6.
ZambranoEEl-HennawyMEhrenkranzRAZeltermanDReyes-MugicaM. Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases. Pediatr Dev Pathol. 2004;7(5):425-432.
6.
KellyDA. Liver complications of pediatric parenteral nutrition—epidemiology. Nutrition. 1998;14(1):153-157.
7.
MossRLAmiiLA. New approaches to understanding the etiology and treatment of total parenteral nutrition–associated cholestasis. Semin Pediatr Surg. 1999;8(3):140-147.
8.
ColeCRFremJCSchmotzerB. The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses. J Pediatr. 2010;156(6):941-947, 947.e1.
9.
SondheimerJMAsturiasECadnapaphornchaiM. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1998;27(2):131-137.
10.
WolfAPohlandtF. Bacterial infection: the main cause of acute cholestasis in newborn infants receiving short-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1989;8(3):297-303.
11.
BlackDDSuttleEAWhitingtonPFWhitingtonGLKoronesSD. The effect of short-term total parenteral nutrition on hepatic function in the human neonate: a prospective randomized study demonstrating alteration of hepatic canalicular function. J Pediatr. 1981;99(3):445-449.
12.
MessingBColombelJFHeresbachDChazouilleresOGalianA. Chronic cholestasis and macronutrient excess in patients treated with prolonged parenteral nutrition. Nutrition. 1992;8(1):30-36.
13.
SpagnuoloMIIorioRVegnenteAGuarinoA. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology. 1996;111(3):716-719.
14.
LevineAMaayanAShamirRDinariGSulkesJSirottaL. Parenteral nutrition–associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab. 1999;12(4): 549-553.
15.
ChenCYTsaoPNChenHLChouHCHsiehWSChangMH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition–associated cholestasis. J Pediatr. 2004;145(3):317-321.
16.
San LuisVABtaicheIF. Ursodiol in patients with parenteral nutrition–associated cholestasis. Ann Pharmacother. 2007;41(11):1867-1872.
17.
PuderMValimCMeiselJA. Parenteral fish oil improves outcomes in patients with parenteral nutrition–associated liver injury. Ann Surg. 2009;250(3):395-402.
18.
GuraKMDugganCPCollierSB. Reversal of parenteral nutrition–associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118(1):e197-e201.
19.
RangelSJCalkinsCMCowlesRA. Parenteral nutrition–associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47(1):225-240.
20.
GuraKMLeeSValimC. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition–associated liver disease. Pediatrics. 2008;121(3):e678-e686.
21.
DiamondIRSterescuAPencharzPBKimJHWalesPW. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48(2):209-215.
22.
ClaytonPTWhitfieldPIyerK. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition. 1998;14(1):158-164.
23.
GrimmingerFWahnHMayerKKissLWalmrathDSeegerW. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med. 1997;155(2):513-519.
24.
WantenGJCalderPC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85(5):1171-1184.
25.
SchmockerCWeylandtKHKahlkeL. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology. 2007;45(4):864-869.
26.
FallonEMLeHDPuderM. Prevention of parenteral nutrition–associated liver disease: role of omega-3 fish oil. Curr Opin Organ Transplant. 2010;15(3):334-340.
27.
BellengerJBellengerSClementL. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension. Faseb J. 2004;18(6):773-775.
28.
de MeijerVEGuraKMLeHDMeiselJAPuderM. Fish oil–based lipid emulsions prevent and reverse parenteral nutrition–associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009;33(5): 541-547.
29.
VenickRSCalkinsK. The impact of intravenous fish oil emulsions on pediatric intestinal failure–associated liver disease. Curr Opin Organ Transplant. 2011;16(3):306-311.
30.
XiongJZhuSZhouYWuHWangC. Regulation of omega-3 fish oil emulsion on the SIRS during the initial stage of severe acute pancreatitis. J Huazhong Univ Sci Technolog Med Sci. 2009;29(1):35-38.
31.
WangXLiWLiNLiJ. Omega-3 fatty acids–supplemented parenteral nutrition decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: a randomized and controlled study. JPEN J Parenter Enteral Nutr. 2008;32(3):236-241.
32.
PluessTTHayozDBergerMM. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 2007;33(5):789-797.
33.
KhorBSLiawSJShihHCWangLS. Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis. Asian J Surg. 2011;34(1):1-10.
34.
BeathSVDaviesPPapadopoulouA. Parenteral nutrition–related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg. 1996;31(4):604-606.
35.
CamposACOlerAMeguidMMChenTY. Liver biochemical and histological changes with graded amounts of total parenteral nutrition. Arch Surg. 1990;125(4):447-450.
36.
MeguidMMChenTYYangZJCamposACHitchDCGleasonJR. Effects of continuous graded total parenteral nutrition on feeding indexes and metabolic concomitants in rats. Am J Physiol. 1991;260 (1, pt 1):E126-E140.
37.
LiSNussbaumMSTeagueDGapenCLDayalRFischerJE. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res. 1988;44(6):639-648.
38.
KaminskiDLAdamsAJellinekM. The effect of hyperalimentation on hepatic lipid content and lipogenic enzyme activity in rats and man. Surgery. 1980;88(1):93-100.
39.
CavicchiMBeauPCrennPDegottCMessingB. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7): 525-532.
40.
PowellEECooksleyWGHansonRSearleJHallidayJWPowellLW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74-80.
41.
MullickFGMoranCAIshakKG. Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. Mod Pathol. 1994;7(2):190-194.
42.
ChanSMcCowenKCBistrianBR. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery. 1999;126(1):28-34.
43.
JavidPJCollierSRichardsonD. The role of enteral nutrition in the reversal of parenteral nutrition–associated liver dysfunction in infants. J Pediatr Surg. 2005;40(6):1015-1018.
44.
CarterBAKarpenSJ. Intestinal failure–associated liver disease: management and treatment strategies past, present, and future. Semin Liver Dis. 2007;27(3):251-258.
45.
SigaletDBoctorDRobertsonM. Improved outcomes in paediatric intestinal failure with aggressive prevention of liver disease. Eur J Pediatr Surg. 2009;19(6):348-353.
46.
MeehanJJGeorgesonKE. Prevention of liver failure in parenteral nutrition: children with short bowel syndrome. J Pediatr Surg. 1997;32(3):473-475.
47.
VanderhoofJALangnasAN. Short-bowel syndrome in children and adults. Gastroenterology. 1997;113(5):1767-1778.
48.
BeauPLabat-LabourdetteJIngrandPBeauchantM. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition–related liver disease?J Hepatol. 1994;20(2):240-244.
49.
ArslanogluSMoroGETauschelHDBoehmG. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2008;46(2):228-231.
50.
GleghornEEMerrittRJSubramanianNRamosA. Phenobarbital does not prevent total parenteral nutrition–associated cholestasis in noninfected neonates. JPEN J Parenter Enteral Nutr. 1986;10(3):282-283.
51.
FielMISauterBWuHS. Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. Clin Gastroenterol Hepatol. 2008;6(8):926-933.
52.
ReimundJMArondelYJolyFMessingBDuclosBBaumannR. Potential usefulness of olive oil–based lipid emulsions in selected situations of home parenteral nutrition–associated liver disease. Clin Nutr. 2004;23(6):1418-1425.
53.
ChenWJYehSL. Effects of fish oil in parenteral nutrition. Nutrition. 2003;19(3):275-279.
54.
AlwaynIPGuraKNoseV. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005;57(3):445-452.
55.
ArayaJRodrigoRVidelaLA. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004;106(6): 635-643.
56.
Van AerdeJEDuerksenDRGramlichL. Intravenous fish oil emulsion attenuates total parenteral nutrition–induced cholestasis in newborn piglets. Pediatr Res. 1999;45(2):202-208.
57.
MeiselJALeHDde MeijerVE. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg. 2011;46(4):666-673.
58.
CalderPC. n-3 fatty acids, inflammation, and immunity—relevance to postsurgical and critically ill patients. Lipids. 2004;39(12):1147-1161.
59.
WalesPWde SilvaNKimJHLecceLSandhuAMooreAM. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40(5):755-762.
60.
TeitelbaumDHTracyTFJrAouthmanyMM. Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition–associated cholestasis. Pediatrics. 2005;115(5):1332-1340.
61.
LeeSIValimCJohnstonP. Impact of fish oil–based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition–associated liver disease. Pediatr Res. 2009;66(6):698-703.
62.
LeHDde MeijerVEZurakowskiDMeiselJAGuraKMPuderM. Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition–associated liver disease. JPEN J Parenter Enteral Nutr. 2010;34(5):477-484.
63.
de MeijerVELeHDMeiselJAGuraKMPuderM. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition–dependent patients. J Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
64.
StrijboschRALeeSArsenaultDA. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008;57(5):698-707.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
